Navigation Links
Sunesis Presents Data Supporting SNS-032's Potential Anticancer,Activity in Multiple Myeloma at the American Association for Cancer,Research Meeting

Results from Non-clinical Studies Confirm Mechanism of Action and Provide Guidance for Dosing

SOUTH SAN FRANCISCO, April 16, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presented non-clinical data demonstrating SNS-032's apoptotic activity in a multiple myeloma model. These data were presented today in a poster session during the Annual Meeting of the American Association for Cancer Research (AACR).

SNS-032, a selective and potent inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, is currently in a Phase 1 clinical trial for B-cell malignancies, including chronic lymphocytic leukemia, multiple myeloma and mantle cell lymphoma. Non-clinical studies were conducted by Sunesis evaluating SNS-032's mechanism of action and in vitro activity against human multiple myeloma cell line RPMI-8226. Acting through inhibition of CDKs 2, 7, and 9, SNS-032 blocks both the cell cycle and transcription to drive apoptosis, or programmed cell death, in multiple myeloma cells upon exposure for six hours. Researchers also noted that exposure to SNS-032 induced down regulation of key anti-apoptotic factors, cell survival proteins, and growth factors that drive the disease. These results confirm that inhibiting CDKs 2, 7 and 9 targets both unregulated cell proliferation and the microenvironment associated with multiple myeloma and support the dosing regimen currently in use in the company's Phase 1 B-cell malignancy clinical trial.

"Data presented today from our non-clinical study of SNS-032 in multiple myeloma cell lines support our hypothesis that targeted inhibition of CDKs 2, 7 and 9 triggers cell death in hematologic cancer," said Daniel C. Adelman, M.D., Senior Vice President, Research and Development. "In addition, these results provide a pharmacologic basis for the dosing regimen being used in our Phase 1 clinical study, and identify potential biomarkers for monitoring activity."

Data were presented today as part of the Targeted Agents and Other Novel Therapies session in poster "SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives apoptosis in the multiple myeloma cell line RPMI-8226" (Abstract #1815).

About SNS-032

SNS-032 is a potent and selective inhibitor of CDKs 2, 7 and 9, which are critical in the communication and relay of signals to promote cellular growth and function. CDK2 is involved in cellular proliferation by regulating the initiation of and progression through the DNA-synthesis phase of the cell cycle. CDK7 and CDK9 are involved in transcriptional regulation of certain proteins involved in cell survival. Inappropriate activity by these CDKs can lead to unregulated proliferation, avoidance of apoptosis and increased cell survival, all of which are hallmarks of cancer. By selectively targeting these CDKs, SNS-032 may halt both aberrant cell proliferation and induce apoptosis.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell cycle and survival signaling. Sunesis is currently conducting Phase 2 clinical trials in lung and ovarian cancer and a Phase 1 clinical trial in acute myeloid leukemia for its lead compound, SNS-595. SNS-032, Sunesis' CDK inhibitor compound, is being evaluated in Phase 1 clinical trials in B-cell malignancies and in advanced solid tumors. The company's Aurora kinase inhibitor, SNS-314 is expected to begin Phase 1 clinical trials in the first half of 2007. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has buil t a broad product candidate portfolio through internal discovery and in-licensing of targeted cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements.

CONTACT: Investors: Eric Bjerkholt, SVP, Corporate Development & Finance,Sunesis Pharmaceuticals, Inc., +1-650-266-3717; Media: Karen L. Bergman,+1-650-575-1509, or Michelle Corral, +1-415-794-8662, both of BCC Partners

Web site: http://www.sunesis.com/

Ticker Symbol: (NASDAQ-NMS:SNSS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
8. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
9. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
10. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
11. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 2016 Research and ... Acute Myeloid Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Myeloid Leukemia epidemiology, Acute Myeloid Leukemia ...
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
(Date:5/3/2016)... 3, 2016  While you may be familiar with watching a film or TV show in ... ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the ... Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Hight-Doland Insurance Agency’s new community involvement ... with Big Brothers Big Sisters of Southwest Louisiana to help provide positive mentoring for ... , Big Brothers Big Sisters of Southwest Louisiana has been helping to guide the ...
(Date:5/4/2016)... Island (PRWEB) , ... May 04, 2016 , ... ... in April 2016. SS&A teamed up with one of the top website design ... information portal contains informative legal articles related to the law firm's main practice ...
(Date:5/4/2016)... ... , ... Recognizing that lifestyle medicine is essential to health and healthcare, ... Katz, MD, MPH, president of the American College of Lifestyle Medicine, as their first ... gratifying,” said Katz. “There is so much opportunity to add years to lives, and ...
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... The ... that ex-supermodel Janice Dickinson needed following breast cancer surgery. In March 2016, the 61-year-old ... a type of breast cancer that occurs in the milk ducts, according to an ...
(Date:5/4/2016)... Prairie du Sac, Wisconsin (PRWEB) , ... ... ... The OMNIFORCE collection delivers next-level compression and support for knees, ankles, and ... a great value. , Innovative 3D flat-bed manufacturing (opposed to ineffective circular ...
Breaking Medicine News(10 mins):